株式会社グローバルインフォメーション
TEL: 044-952-0102
市場調査レポート

心血管治療薬の世界市場

Cardiovascular Drugs

発行 Global Industry Analysts, Inc. 商品コード 912508
出版日 ページ情報 英文 265 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=111.19円で換算しております。

ご注意:Single user licenseはDRM(デジタル著作権管理システム)付PDFとなります。
PDFの閲覧には Adobe Digital Editions (無償)のインストールが必要となります。
認証されたPC上のみでの閲覧と、1回のプリントアウトが可能となっております。

Back to Top
心血管治療薬の世界市場 Cardiovascular Drugs
出版日: 2019年10月01日 ページ情報: 英文 265 Pages
概要

当レポートでは、世界における心血管治療薬市場の概要、動向・発展への影響因子の分析、競合企業と市場シェア、世界および地域・主要国別の市場規模の推移と予測、主要企業のプロファイルなどをまとめています。

第1章 イントロダクション・調査手法・調査範囲

第2章 エグゼクティブサマリー

  • 市場概要
    • 世界市場における企業シェア
    • 世界の心血管治療薬市場における企業シェアのシナリオ
  • 主要企業
  • 市場の動向と発展因子
  • 世界市場の見通し

第3章 市場分析

  • 地域別市場の分析
    • 米国
    • カナダ
    • 日本
    • 中国
    • 欧州
    • フランス
    • ドイツ
    • イタリア
    • 英国
    • スペイン
    • ロシア
    • その他欧州
    • アジア太平洋地域
    • オーストラリア
    • インド
    • 韓国
    • その他アジア太平洋地域
    • ラテンアメリカ
    • アルゼンチン
    • ブラジル
    • メキシコ
    • その他ラテンアメリカ
    • 中東
    • イラン
    • イスラエル
    • サウジアラビア
    • アラブ首長国連邦
    • その他中東
    • アフリカ

第4章 競合企業

  • ABBOTT LABORATORIES
  • アステラス製薬
  • ASTRAZENECA PLC
  • BAYER AG
  • BOEHRINGER INGELHEIM INTERNATIONAL GMBH
  • BRISTOL-MYERS SQUIBB COMPANY
  • ELI LILLY AND COMPANY
  • F. HOFFMANN-LA ROCHE AG
  • GILEAD SCIENCES
  • JOHNSON & JOHNSON
  • MERCK & CO., INC.
  • NOVARTIS INTERNATIONAL AG
  • 大塚製薬
  • PFIZER
  • SANOFI-AVENTIS US
  • 武田薬品工業

第5章 調査資料

目次
Product Code: MCP-1698

Cardiovascular Drugs market worldwide is projected to grow by US$7.8 Billion, driven by a compounded growth of 1.4%. Renin-Angiotensin System Blockers, one of the segments analyzed and sized in this study, displays the potential to grow at over 1.1%. The shifting dynamics supporting this growth makes it critical for businesses in this space to keep abreast of the changing pulse of the market. Poised to reach over US$7.6 Billion by the year 2025, Renin-Angiotensin System Blockers will bring in healthy gains adding significant momentum to global growth.

Representing the developed world, the United States will maintain a 1.1% growth momentum. Within Europe, which continues to remain an important element in the world economy, Germany will add over US$344.2 Million to the region's size and clout in the next 5 to 6 years. Over US$242.8 Million worth of projected demand in the region will come from Rest of Europe markets. In Japan, Renin-Angiotensin System Blockers will reach a market size of US$174.8 Million by the close of the analysis period. As the world's second largest economy and the new game changer in global markets, China exhibits the potential to grow at 1.9% over the next couple of years and add approximately US$1.9 Billion in terms of addressable opportunity for the picking by aspiring businesses and their astute leaders. Presented in visually rich graphics are these and many more need-to-know quantitative data important in ensuring quality of strategy decisions, be it entry into new markets or allocation of resources within a portfolio. Several macroeconomic factors and internal market forces will shape growth and development of demand patterns in emerging countries in Asia-Pacific, Latin America and the Middle East. All research viewpoints presented are based on validated engagements from influencers in the market, whose opinions supersede all other research methodologies.

Competitors identified in this market include, among others,, Abbott Laboratories, Inc.; Astellas Pharma US, Inc.; AstraZeneca PLC; Bayer AG; Boehringer Ingelheim GmbH; Bristol-Myers Squibb Company; Eli Lilly and Company; F. Hoffmann-La Roche AG; Gilead Sciences, Inc.; Johnson & Johnson; Merck & Co., Inc.; Novartis International AG; Otsuka Pharmaceutical Co., Ltd.; Pfizer, Inc.; Sanofi-aventis U.S. LLC; Takeda Pharmaceutical Co., Ltd.

TABLE OF CONTENTS

I. INTRODUCTION, METHODOLOGY & REPORT SCOPE

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW

  • Global Competitor Market Shares
  • Cardiovascular Drugs Competitor Market Share Scenario Worldwide (in %): 2019 & 2028

2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS

4. GLOBAL MARKET PERSPECTIVE

  • TABLE 1: Cardiovascular Drugs Global Market Estimates and Forecasts in US$ Million by Region/Country: 2018-2025
  • TABLE 2: Cardiovascular Drugs Global Retrospective Market Scenario in US$ Million by Region/Country: 2009-2017
  • TABLE 3: Cardiovascular Drugs Market Share Shift across Key Geographies Worldwide: 2009 VS 2019 VS 2025
  • TABLE 4: Renin-Angiotensin System Blockers (Drug Class) World Market by Region/Country in US$ Million: 2018 to 2025
  • TABLE 5: Renin-Angiotensin System Blockers (Drug Class) Historic Market Analysis by Region/Country in US$ Million: 2009 to 2017
  • TABLE 6: Renin-Angiotensin System Blockers (Drug Class) Market Share Breakdown of Worldwide Sales by Region/Country: 2009 VS 2019 VS 2025
  • TABLE 7: Beta Blockers (Drug Class) Potential Growth Markets Worldwide in US$ Million: 2018 to 2025
  • TABLE 8: Beta Blockers (Drug Class) Historic Market Perspective by Region/Country in US$ Million: 2009 to 2017
  • TABLE 9: Beta Blockers (Drug Class) Market Sales Breakdown by Region/Country in Percentage: 2009 VS 2019 VS 2025
  • TABLE 10: Diuretics (Drug Class) Geographic Market Spread Worldwide in US$ Million: 2018 to 2025
  • TABLE 11: Diuretics (Drug Class) Region Wise Breakdown of Global Historic Demand in US$ Million: 2009 to 2017
  • TABLE 12: Diuretics (Drug Class) Market Share Distribution in Percentage by Region/Country: 2009 VS 2019 VS 2025
  • TABLE 13: Anti-Clotting Agents (Drug Class) World Market Estimates and Forecasts by Region/Country in US$ Million: 2018 to 2025
  • TABLE 14: Anti-Clotting Agents (Drug Class) Market Historic Review by Region/Country in US$ Million: 2009 to 2017
  • TABLE 15: Anti-Clotting Agents (Drug Class) Market Share Breakdown by Region/Country: 2009 VS 2019 VS 2025
  • TABLE 16: Antihyperlipidemics (Drug Class) World Market by Region/Country in US$ Million: 2018 to 2025
  • TABLE 17: Antihyperlipidemics (Drug Class) Historic Market Analysis by Region/Country in US$ Million: 2009 to 2017
  • TABLE 18: Antihyperlipidemics (Drug Class) Market Share Distribution in Percentage by Region/Country: 2009 VS 2019 VS 2025
  • TABLE 19: Other Drug Classes (Drug Class) World Market Estimates and Forecasts in US$ Million by Region/Country: 2018 to 2025
  • TABLE 20: Other Drug Classes (Drug Class) Market Worldwide Historic Review by Region/Country in US$ Million: 2009 to 2017
  • TABLE 21: Other Drug Classes (Drug Class) Market Percentage Share Distribution by Region/Country: 2009 VS 2019 VS 2025
  • TABLE 22: Hypertension (Indication) Market Opportunity Analysis Worldwide in US$ Million by Region/Country: 2018 to 2025
  • TABLE 23: Hypertension (Indication) Global Historic Demand in US$ Million by Region/Country: 2009 to 2017
  • TABLE 24: Hypertension (Indication) Market Share Distribution in Percentage by Region/Country: 2009 VS 2019 VS 2025
  • TABLE 25: Hyperlipidemia (Indication) World Market by Region/Country in US$ Million: 2018 to 2025
  • TABLE 26: Hyperlipidemia (Indication) Historic Market Analysis by Region/Country in US$ Million: 2009 to 2017
  • TABLE 27: Hyperlipidemia (Indication) Market Share Breakdown of Worldwide Sales by Region/Country: 2009 VS 2019 VS 2025
  • TABLE 28: Coronary Artery Disease & Peripheral Artery Disease (Indication) Potential Growth Markets Worldwide in US$ Million: 2018 to 2025
  • TABLE 29: Coronary Artery Disease & Peripheral Artery Disease (Indication) Historic Market Perspective by Region/Country in US$ Million: 2009 to 2017
  • TABLE 30: Coronary Artery Disease & Peripheral Artery Disease (Indication) Market Sales Breakdown by Region/Country in Percentage: 2009 VS 2019 VS 2025
  • TABLE 31: Other Indications (Indication) Geographic Market Spread Worldwide in US$ Million: 2018 to 2025
  • TABLE 32: Other Indications (Indication) Region Wise Breakdown of Global Historic Demand in US$ Million: 2009 to 2017
  • TABLE 33: Other Indications (Indication) Market Share Distribution in Percentage by Region/Country: 2009 VS 2019 VS 2025

III. MARKET ANALYSIS

  • GEOGRAPHIC MARKET ANALYSIS
  • UNITED STATES
    • Market Facts & Figures
    • US Cardiovascular Drugs Market Share (in %) by Company: 2019 & 2025
    • TABLE 34: United States Cardiovascular Drugs Market Estimates and Projections in US$ Million by Drug Class: 2018 to 2025
    • TABLE 35: Cardiovascular Drugs Market in the United States by Drug Class: A Historic Review in US$ Million for 2009-2017
    • TABLE 36: United States Cardiovascular Drugs Market Share Breakdown by Drug Class: 2009 VS 2019 VS 2025
    • TABLE 37: United States Cardiovascular Drugs Market Estimates and Projections in US$ Million by Indication: 2018 to 2025
    • TABLE 38: Cardiovascular Drugs Market in the United States by Indication: A Historic Review in US$ Million for 2009-2017
    • TABLE 39: United States Cardiovascular Drugs Market Share Breakdown by Indication: 2009 VS 2019 VS 2025
  • CANADA
    • TABLE 40: Canadian Cardiovascular Drugs Market Estimates and Forecasts in US$ Million by Drug Class: 2018 to 2025
    • TABLE 41: Canadian Cardiovascular Drugs Historic Market Review by Drug Class in US$ Million: 2009-2017
    • TABLE 42: Cardiovascular Drugs Market in Canada: Percentage Share Breakdown of Sales by Drug Class for 2009, 2019, and 2025
    • TABLE 43: Canadian Cardiovascular Drugs Market Estimates and Forecasts in US$ Million by Indication: 2018 to 2025
    • TABLE 44: Canadian Cardiovascular Drugs Historic Market Review by Indication in US$ Million: 2009-2017
    • TABLE 45: Cardiovascular Drugs Market in Canada: Percentage Share Breakdown of Sales by Indication for 2009, 2019, and 2025
  • JAPAN
    • TABLE 46: Japanese Market for Cardiovascular Drugs: Annual Sales Estimates and Projections in US$ Million by Drug Class for the Period 2018-2025
    • TABLE 47: Cardiovascular Drugs Market in Japan: Historic Sales Analysis in US$ Million by Drug Class for the Period 2009-2017
    • TABLE 48: Japanese Cardiovascular Drugs Market Share Analysis by Drug Class: 2009 VS 2019 VS 2025
    • TABLE 49: Japanese Market for Cardiovascular Drugs: Annual Sales Estimates and Projections in US$ Million by Indication for the Period 2018-2025
    • TABLE 50: Cardiovascular Drugs Market in Japan: Historic Sales Analysis in US$ Million by Indication for the Period 2009-2017
    • TABLE 51: Japanese Cardiovascular Drugs Market Share Analysis by Indication: 2009 VS 2019 VS 2025
  • CHINA
    • TABLE 52: Chinese Cardiovascular Drugs Market Growth Prospects in US$ Million by Drug Class for the Period 2018-2025
    • TABLE 53: Cardiovascular Drugs Historic Market Analysis in China in US$ Million by Drug Class: 2009-2017
    • TABLE 54: Chinese Cardiovascular Drugs Market by Drug Class: Percentage Breakdown of Sales for 2009, 2019, and 2025
    • TABLE 55: Chinese Cardiovascular Drugs Market Growth Prospects in US$ Million by Indication for the Period 2018-2025
    • TABLE 56: Cardiovascular Drugs Historic Market Analysis in China in US$ Million by Indication: 2009-2017
    • TABLE 57: Chinese Cardiovascular Drugs Market by Indication: Percentage Breakdown of Sales for 2009, 2019, and 2025
  • EUROPE
    • Market Facts & Figures
    • European Cardiovascular Drugs Market: Competitor Market Share Scenario (in %) for 2019 & 2025
    • TABLE 58: European Cardiovascular Drugs Market Demand Scenario in US$ Million by Region/Country: 2018-2025
    • TABLE 59: Cardiovascular Drugs Market in Europe: A Historic Market Perspective in US$ Million by Region/Country for the Period 2009-2017
    • TABLE 60: European Cardiovascular Drugs Market Share Shift by Region/Country: 2009 VS 2019 VS 2025
    • TABLE 61: European Cardiovascular Drugs Market Estimates and Forecasts in US$ Million by Drug Class: 2018-2025
    • TABLE 62: Cardiovascular Drugs Market in Europe in US$ Million by Drug Class: A Historic Review for the Period 2009-2017
    • TABLE 63: European Cardiovascular Drugs Market Share Breakdown by Drug Class: 2009 VS 2019 VS 2025
    • TABLE 64: European Cardiovascular Drugs Market Estimates and Forecasts in US$ Million by Indication: 2018-2025
    • TABLE 65: Cardiovascular Drugs Market in Europe in US$ Million by Indication: A Historic Review for the Period 2009-2017
    • TABLE 66: European Cardiovascular Drugs Market Share Breakdown by Indication: 2009 VS 2019 VS 2025
  • FRANCE
    • TABLE 67: Cardiovascular Drugs Market in France by Drug Class: Estimates and Projections in US$ Million for the Period 2018-2025
    • TABLE 68: French Cardiovascular Drugs Historic Market Scenario in US$ Million by Drug Class: 2009-2017
    • TABLE 69: French Cardiovascular Drugs Market Share Analysis by Drug Class: 2009 VS 2019 VS 2025
    • TABLE 70: Cardiovascular Drugs Market in France by Indication: Estimates and Projections in US$ Million for the Period 2018-2025
    • TABLE 71: French Cardiovascular Drugs Historic Market Scenario in US$ Million by Indication: 2009-2017
    • TABLE 72: French Cardiovascular Drugs Market Share Analysis by Indication: 2009 VS 2019 VS 2025
  • GERMANY
    • TABLE 73: Cardiovascular Drugs Market in Germany: Recent Past, Current and Future Analysis in US$ Million by Drug Class for the Period 2018-2025
    • TABLE 74: German Cardiovascular Drugs Historic Market Analysis in US$ Million by Drug Class: 2009-2017
    • TABLE 75: German Cardiovascular Drugs Market Share Breakdown by Drug Class: 2009 VS 2019 VS 2025
    • TABLE 76: Cardiovascular Drugs Market in Germany: Recent Past, Current and Future Analysis in US$ Million by Indication for the Period 2018-2025
    • TABLE 77: German Cardiovascular Drugs Historic Market Analysis in US$ Million by Indication: 2009-2017
    • TABLE 78: German Cardiovascular Drugs Market Share Breakdown by Indication: 2009 VS 2019 VS 2025
  • ITALY
    • TABLE 79: Italian Cardiovascular Drugs Market Growth Prospects in US$ Million by Drug Class for the Period 2018-2025
    • TABLE 80: Cardiovascular Drugs Historic Market Analysis in Italy in US$ Million by Drug Class: 2009-2017
    • TABLE 81: Italian Cardiovascular Drugs Market by Drug Class: Percentage Breakdown of Sales for 2009, 2019, and 2025
    • TABLE 82: Italian Cardiovascular Drugs Market Growth Prospects in US$ Million by Indication for the Period 2018-2025
    • TABLE 83: Cardiovascular Drugs Historic Market Analysis in Italy in US$ Million by Indication: 2009-2017
    • TABLE 84: Italian Cardiovascular Drugs Market by Indication: Percentage Breakdown of Sales for 2009, 2019, and 2025
  • UNITED KINGDOM
    • TABLE 85: United Kingdom Market for Cardiovascular Drugs: Annual Sales Estimates and Projections in US$ Million by Drug Class for the Period 2018-2025
    • TABLE 86: Cardiovascular Drugs Market in the United Kingdom: Historic Sales Analysis in US$ Million by Drug Class for the Period 2009-2017
    • TABLE 87: United Kingdom Cardiovascular Drugs Market Share Analysis by Drug Class: 2009 VS 2019 VS 2025
    • TABLE 88: United Kingdom Market for Cardiovascular Drugs: Annual Sales Estimates and Projections in US$ Million by Indication for the Period 2018-2025
    • TABLE 89: Cardiovascular Drugs Market in the United Kingdom: Historic Sales Analysis in US$ Million by Indication for the Period 2009-2017
    • TABLE 90: United Kingdom Cardiovascular Drugs Market Share Analysis by Indication: 2009 VS 2019 VS 2025
  • SPAIN
    • TABLE 91: Spanish Cardiovascular Drugs Market Estimates and Forecasts in US$ Million by Drug Class: 2018 to 2025
    • TABLE 92: Spanish Cardiovascular Drugs Historic Market Review by Drug Class in US$ Million: 2009-2017
    • TABLE 93: Cardiovascular Drugs Market in Spain: Percentage Share Breakdown of Sales by Drug Class for 2009, 2019, and 2025
    • TABLE 94: Spanish Cardiovascular Drugs Market Estimates and Forecasts in US$ Million by Indication: 2018 to 2025
    • TABLE 95: Spanish Cardiovascular Drugs Historic Market Review by Indication in US$ Million: 2009-2017
    • TABLE 96: Cardiovascular Drugs Market in Spain: Percentage Share Breakdown of Sales by Indication for 2009, 2019, and 2025
  • RUSSIA
    • TABLE 97: Russian Cardiovascular Drugs Market Estimates and Projections in US$ Million by Drug Class: 2018 to 2025
    • TABLE 98: Cardiovascular Drugs Market in Russia by Drug Class: A Historic Review in US$ Million for 2009-2017
    • TABLE 99: Russian Cardiovascular Drugs Market Share Breakdown by Drug Class: 2009 VS 2019 VS 2025
    • TABLE 100: Russian Cardiovascular Drugs Market Estimates and Projections in US$ Million by Indication: 2018 to 2025
    • TABLE 101: Cardiovascular Drugs Market in Russia by Indication: A Historic Review in US$ Million for 2009-2017
    • TABLE 102: Russian Cardiovascular Drugs Market Share Breakdown by Indication: 2009 VS 2019 VS 2025
  • REST OF EUROPE
    • TABLE 103: Rest of Europe Cardiovascular Drugs Market Estimates and Forecasts in US$ Million by Drug Class: 2018-2025
    • TABLE 104: Cardiovascular Drugs Market in Rest of Europe in US$ Million by Drug Class: A Historic Review for the Period 2009-2017
    • TABLE 105: Rest of Europe Cardiovascular Drugs Market Share Breakdown by Drug Class: 2009 VS 2019 VS 2025
    • TABLE 106: Rest of Europe Cardiovascular Drugs Market Estimates and Forecasts in US$ Million by Indication: 2018-2025
    • TABLE 107: Cardiovascular Drugs Market in Rest of Europe in US$ Million by Indication: A Historic Review for the Period 2009-2017
    • TABLE 108: Rest of Europe Cardiovascular Drugs Market Share Breakdown by Indication: 2009 VS 2019 VS 2025
  • ASIA-PACIFIC
    • TABLE 109: Asia-Pacific Cardiovascular Drugs Market Estimates and Forecasts in US$ Million by Region/Country: 2018-2025
    • TABLE 110: Cardiovascular Drugs Market in Asia-Pacific: Historic Market Analysis in US$ Million by Region/Country for the Period 2009-2017
    • TABLE 111: Asia-Pacific Cardiovascular Drugs Market Share Analysis by Region/Country: 2009 VS 2019 VS 2025
    • TABLE 112: Cardiovascular Drugs Market in Asia-Pacific by Drug Class: Estimates and Projections in US$ Million for the Period 2018-2025
    • TABLE 113: Asia-Pacific Cardiovascular Drugs Historic Market Scenario in US$ Million by Drug Class: 2009-2017
    • TABLE 114: Asia-Pacific Cardiovascular Drugs Market Share Analysis by Drug Class: 2009 VS 2019 VS 2025
    • TABLE 115: Cardiovascular Drugs Market in Asia-Pacific by Indication: Estimates and Projections in US$ Million for the Period 2018-2025
    • TABLE 116: Asia-Pacific Cardiovascular Drugs Historic Market Scenario in US$ Million by Indication: 2009-2017
    • TABLE 117: Asia-Pacific Cardiovascular Drugs Market Share Analysis by Indication: 2009 VS 2019 VS 2025
  • AUSTRALIA
    • TABLE 118: Cardiovascular Drugs Market in Australia: Recent Past, Current and Future Analysis in US$ Million by Drug Class for the Period 2018-2025
    • TABLE 119: Australian Cardiovascular Drugs Historic Market Analysis in US$ Million by Drug Class: 2009-2017
    • TABLE 120: Australian Cardiovascular Drugs Market Share Breakdown by Drug Class: 2009 VS 2019 VS 2025
    • TABLE 121: Cardiovascular Drugs Market in Australia: Recent Past, Current and Future Analysis in US$ Million by Indication for the Period 2018-2025
    • TABLE 122: Australian Cardiovascular Drugs Historic Market Analysis in US$ Million by Indication: 2009-2017
    • TABLE 123: Australian Cardiovascular Drugs Market Share Breakdown by Indication: 2009 VS 2019 VS 2025
  • INDIA
    • TABLE 124: Indian Cardiovascular Drugs Market Estimates and Forecasts in US$ Million by Drug Class: 2018 to 2025
    • TABLE 125: Indian Cardiovascular Drugs Historic Market Review by Drug Class in US$ Million: 2009-2017
    • TABLE 126: Cardiovascular Drugs Market in India: Percentage Share Breakdown of Sales by Drug Class for 2009, 2019, and 2025
    • TABLE 127: Indian Cardiovascular Drugs Market Estimates and Forecasts in US$ Million by Indication: 2018 to 2025
    • TABLE 128: Indian Cardiovascular Drugs Historic Market Review by Indication in US$ Million: 2009-2017
    • TABLE 129: Cardiovascular Drugs Market in India: Percentage Share Breakdown of Sales by Indication for 2009, 2019, and 2025
  • SOUTH KOREA
    • TABLE 130: Cardiovascular Drugs Market in South Korea: Recent Past, Current and Future Analysis in US$ Million by Drug Class for the Period 2018-2025
    • TABLE 131: South Korean Cardiovascular Drugs Historic Market Analysis in US$ Million by Drug Class: 2009-2017
    • TABLE 132: Cardiovascular Drugs Market Share Distribution in South Korea by Drug Class: 2009 VS 2019 VS 2025
    • TABLE 133: Cardiovascular Drugs Market in South Korea: Recent Past, Current and Future Analysis in US$ Million by Indication for the Period 2018-2025
    • TABLE 134: South Korean Cardiovascular Drugs Historic Market Analysis in US$ Million by Indication: 2009-2017
    • TABLE 135: Cardiovascular Drugs Market Share Distribution in South Korea by Indication: 2009 VS 2019 VS 2025
  • REST OF ASIA-PACIFIC
    • TABLE 136: Rest of Asia-Pacific Market for Cardiovascular Drugs: Annual Sales Estimates and Projections in US$ Million by Drug Class for the Period 2018-2025
    • TABLE 137: Cardiovascular Drugs Market in Rest of Asia-Pacific: Historic Sales Analysis in US$ Million by Drug Class for the Period 2009-2017
    • TABLE 138: Rest of Asia-Pacific Cardiovascular Drugs Market Share Analysis by Drug Class: 2009 VS 2019 VS 2025
    • TABLE 139: Rest of Asia-Pacific Market for Cardiovascular Drugs: Annual Sales Estimates and Projections in US$ Million by Indication for the Period 2018-2025
    • TABLE 140: Cardiovascular Drugs Market in Rest of Asia-Pacific: Historic Sales Analysis in US$ Million by Indication for the Period 2009-2017
    • TABLE 141: Rest of Asia-Pacific Cardiovascular Drugs Market Share Analysis by Indication: 2009 VS 2019 VS 2025
  • LATIN AMERICA
    • TABLE 142: Latin American Cardiovascular Drugs Market Trends by Region/Country in US$ Million: 2018-2025
    • TABLE 143: Cardiovascular Drugs Market in Latin America in US$ Million by Region/Country: A Historic Perspective for the Period 2009-2017
    • TABLE 144: Latin American Cardiovascular Drugs Market Percentage Breakdown of Sales by Region/Country: 2009, 2019, and 2025
    • TABLE 145: Latin American Cardiovascular Drugs Market Growth Prospects in US$ Million by Drug Class for the Period 2018-2025
    • TABLE 146: Cardiovascular Drugs Historic Market Analysis in Latin America in US$ Million by Drug Class: 2009-2017
    • TABLE 147: Latin American Cardiovascular Drugs Market by Drug Class: Percentage Breakdown of Sales for 2009, 2019, and 2025
    • TABLE 148: Latin American Cardiovascular Drugs Market Growth Prospects in US$ Million by Indication for the Period 2018-2025
    • TABLE 149: Cardiovascular Drugs Historic Market Analysis in Latin America in US$ Million by Indication: 2009-2017
    • TABLE 150: Latin American Cardiovascular Drugs Market by Indication: Percentage Breakdown of Sales for 2009, 2019, and 2025
  • ARGENTINA
    • TABLE 151: Argentinean Cardiovascular Drugs Market Estimates and Forecasts in US$ Million by Drug Class: 2018-2025
    • TABLE 152: Cardiovascular Drugs Market in Argentina in US$ Million by Drug Class: A Historic Review for the Period 2009-2017
    • TABLE 153: Argentinean Cardiovascular Drugs Market Share Breakdown by Drug Class: 2009 VS 2019 VS 2025
    • TABLE 154: Argentinean Cardiovascular Drugs Market Estimates and Forecasts in US$ Million by Indication: 2018-2025
    • TABLE 155: Cardiovascular Drugs Market in Argentina in US$ Million by Indication: A Historic Review for the Period 2009-2017
    • TABLE 156: Argentinean Cardiovascular Drugs Market Share Breakdown by Indication: 2009 VS 2019 VS 2025
  • BRAZIL
    • TABLE 157: Cardiovascular Drugs Market in Brazil by Drug Class: Estimates and Projections in US$ Million for the Period 2018-2025
    • TABLE 158: Brazilian Cardiovascular Drugs Historic Market Scenario in US$ Million by Drug Class: 2009-2017
    • TABLE 159: Brazilian Cardiovascular Drugs Market Share Analysis by Drug Class: 2009 VS 2019 VS 2025
    • TABLE 160: Cardiovascular Drugs Market in Brazil by Indication: Estimates and Projections in US$ Million for the Period 2018-2025
    • TABLE 161: Brazilian Cardiovascular Drugs Historic Market Scenario in US$ Million by Indication: 2009-2017
    • TABLE 162: Brazilian Cardiovascular Drugs Market Share Analysis by Indication: 2009 VS 2019 VS 2025
  • MEXICO
    • TABLE 163: Cardiovascular Drugs Market in Mexico: Recent Past, Current and Future Analysis in US$ Million by Drug Class for the Period 2018-2025
    • TABLE 164: Mexican Cardiovascular Drugs Historic Market Analysis in US$ Million by Drug Class: 2009-2017
    • TABLE 165: Mexican Cardiovascular Drugs Market Share Breakdown by Drug Class: 2009 VS 2019 VS 2025
    • TABLE 166: Cardiovascular Drugs Market in Mexico: Recent Past, Current and Future Analysis in US$ Million by Indication for the Period 2018-2025
    • TABLE 167: Mexican Cardiovascular Drugs Historic Market Analysis in US$ Million by Indication: 2009-2017
    • TABLE 168: Mexican Cardiovascular Drugs Market Share Breakdown by Indication: 2009 VS 2019 VS 2025
  • REST OF LATIN AMERICA
    • TABLE 169: Rest of Latin America Cardiovascular Drugs Market Estimates and Projections in US$ Million by Drug Class: 2018 to 2025
    • TABLE 170: Cardiovascular Drugs Market in Rest of Latin America by Drug Class: A Historic Review in US$ Million for 2009-2017
    • TABLE 171: Rest of Latin America Cardiovascular Drugs Market Share Breakdown by Drug Class: 2009 VS 2019 VS 2025
    • TABLE 172: Rest of Latin America Cardiovascular Drugs Market Estimates and Projections in US$ Million by Indication: 2018 to 2025
    • TABLE 173: Cardiovascular Drugs Market in Rest of Latin America by Indication: A Historic Review in US$ Million for 2009-2017
    • TABLE 174: Rest of Latin America Cardiovascular Drugs Market Share Breakdown by Indication: 2009 VS 2019 VS 2025
  • MIDDLE EAST
    • TABLE 175: The Middle East Cardiovascular Drugs Market Estimates and Forecasts in US$ Million by Region/Country: 2018-2025
    • TABLE 176: Cardiovascular Drugs Market in the Middle East by Region/Country in US$ Million: 2009-2017
    • TABLE 177: The Middle East Cardiovascular Drugs Market Share Breakdown by Region/Country: 2009, 2019, and 2025
    • TABLE 178: The Middle East Cardiovascular Drugs Market Estimates and Forecasts in US$ Million by Drug Class: 2018 to 2025
    • TABLE 179: The Middle East Cardiovascular Drugs Historic Market by Drug Class in US$ Million: 2009-2017
    • TABLE 180: Cardiovascular Drugs Market in the Middle East: Percentage Share Breakdown of Sales by Drug Class for 2009, 2019, and 2025
    • TABLE 181: The Middle East Cardiovascular Drugs Market Estimates and Forecasts in US$ Million by Indication: 2018 to 2025
    • TABLE 182: The Middle East Cardiovascular Drugs Historic Market by Indication in US$ Million: 2009-2017
    • TABLE 183: Cardiovascular Drugs Market in the Middle East: Percentage Share Breakdown of Sales by Indication for 2009, 2019, and 2025
  • IRAN
    • TABLE 184: Iranian Market for Cardiovascular Drugs: Annual Sales Estimates and Projections in US$ Million by Drug Class for the Period 2018-2025
    • TABLE 185: Cardiovascular Drugs Market in Iran: Historic Sales Analysis in US$ Million by Drug Class for the Period 2009-2017
    • TABLE 186: Iranian Cardiovascular Drugs Market Share Analysis by Drug Class: 2009 VS 2019 VS 2025
    • TABLE 187: Iranian Market for Cardiovascular Drugs: Annual Sales Estimates and Projections in US$ Million by Indication for the Period 2018-2025
    • TABLE 188: Cardiovascular Drugs Market in Iran: Historic Sales Analysis in US$ Million by Indication for the Period 2009-2017
    • TABLE 189: Iranian Cardiovascular Drugs Market Share Analysis by Indication: 2009 VS 2019 VS 2025
  • ISRAEL
    • TABLE 190: Israeli Cardiovascular Drugs Market Estimates and Forecasts in US$ Million by Drug Class: 2018-2025
    • TABLE 191: Cardiovascular Drugs Market in Israel in US$ Million by Drug Class: A Historic Review for the Period 2009-2017
    • TABLE 192: Israeli Cardiovascular Drugs Market Share Breakdown by Drug Class: 2009 VS 2019 VS 2025
    • TABLE 193: Israeli Cardiovascular Drugs Market Estimates and Forecasts in US$ Million by Indication: 2018-2025
    • TABLE 194: Cardiovascular Drugs Market in Israel in US$ Million by Indication: A Historic Review for the Period 2009-2017
    • TABLE 195: Israeli Cardiovascular Drugs Market Share Breakdown by Indication: 2009 VS 2019 VS 2025
  • SAUDI ARABIA
    • TABLE 196: Saudi Arabian Cardiovascular Drugs Market Growth Prospects in US$ Million by Drug Class for the Period 2018-2025
    • TABLE 197: Cardiovascular Drugs Historic Market Analysis in Saudi Arabia in US$ Million by Drug Class: 2009-2017
    • TABLE 198: Saudi Arabian Cardiovascular Drugs Market by Drug Class: Percentage Breakdown of Sales for 2009, 2019, and 2025
    • TABLE 199: Saudi Arabian Cardiovascular Drugs Market Growth Prospects in US$ Million by Indication for the Period 2018-2025
    • TABLE 200: Cardiovascular Drugs Historic Market Analysis in Saudi Arabia in US$ Million by Indication: 2009-2017
    • TABLE 201: Saudi Arabian Cardiovascular Drugs Market by Indication: Percentage Breakdown of Sales for 2009, 2019, and 2025
  • UNITED ARAB EMIRATES
    • TABLE 202: Cardiovascular Drugs Market in the United Arab Emirates: Recent Past, Current and Future Analysis in US$ Million by Drug Class for the Period 2018-2025
    • TABLE 203: United Arab Emirates Cardiovascular Drugs Historic Market Analysis in US$ Million by Drug Class: 2009-2017
    • TABLE 204: Cardiovascular Drugs Market Share Distribution in United Arab Emirates by Drug Class: 2009 VS 2019 VS 2025
    • TABLE 205: Cardiovascular Drugs Market in the United Arab Emirates: Recent Past, Current and Future Analysis in US$ Million by Indication for the Period 2018-2025
    • TABLE 206: United Arab Emirates Cardiovascular Drugs Historic Market Analysis in US$ Million by Indication: 2009-2017
    • TABLE 207: Cardiovascular Drugs Market Share Distribution in United Arab Emirates by Indication: 2009 VS 2019 VS 2025
  • REST OF MIDDLE EAST
    • TABLE 208: Cardiovascular Drugs Market in Rest of Middle East: Recent Past, Current and Future Analysis in US$ Million by Drug Class for the Period 2018-2025
    • TABLE 209: Rest of Middle East Cardiovascular Drugs Historic Market Analysis in US$ Million by Drug Class: 2009-2017
    • TABLE 210: Rest of Middle East Cardiovascular Drugs Market Share Breakdown by Drug Class: 2009 VS 2019 VS 2025
    • TABLE 211: Cardiovascular Drugs Market in Rest of Middle East: Recent Past, Current and Future Analysis in US$ Million by Indication for the Period 2018-2025
    • TABLE 212: Rest of Middle East Cardiovascular Drugs Historic Market Analysis in US$ Million by Indication: 2009-2017
    • TABLE 213: Rest of Middle East Cardiovascular Drugs Market Share Breakdown by Indication: 2009 VS 2019 VS 2025
  • AFRICA
    • TABLE 214: African Cardiovascular Drugs Market Estimates and Projections in US$ Million by Drug Class: 2018 to 2025
    • TABLE 215: Cardiovascular Drugs Market in Africa by Drug Class: A Historic Review in US$ Million for 2009-2017
    • TABLE 216: African Cardiovascular Drugs Market Share Breakdown by Drug Class: 2009 VS 2019 VS 2025
    • TABLE 217: African Cardiovascular Drugs Market Estimates and Projections in US$ Million by Indication: 2018 to 2025
    • TABLE 218: Cardiovascular Drugs Market in Africa by Indication: A Historic Review in US$ Million for 2009-2017
    • TABLE 219: African Cardiovascular Drugs Market Share Breakdown by Indication: 2009 VS 2019 VS 2025

IV. COMPETITION

  • ABBOTT LABORATORIES
  • ASTELLAS PHARMA US
  • ASTRAZENECA PLC
  • BAYER AG
  • BOEHRINGER INGELHEIM INTERNATIONAL GMBH
  • BRISTOL-MYERS SQUIBB COMPANY
  • ELI LILLY AND COMPANY
  • F. HOFFMANN-LA ROCHE AG
  • GILEAD SCIENCES
  • JOHNSON & JOHNSON
  • MERCK & CO., INC.
  • NOVARTIS INTERNATIONAL AG
  • OTSUKA PHARMACEUTICAL
  • PFIZER
  • SANOFI-AVENTIS US
  • TAKEDA PHARMACEUTICAL COMPANY LIMITED

V. CURATED RESEARCH

Back to Top